Martinsried, Germany, July 7th, 2010. Intana Bioscience GmbH announced today that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium. Under the agreement, Intana will provide its proprietary Fluorescent Cross Correlation Spectroscopy (FCCS) technology platform to screen for small molecule inhibitors of a set of target proteins.
FCCS is a spectroscopic method to measure the interactions of molecules in solution, based on the sensitive detection of single molecules. The proprietary technology of Intana Bioscience allows FCCS to be performed in cellular lysates, thereby characterizing the interactions between small molecules and their target proteins in approximately physiological conditions.
In the course of this collaboration, Intana will develop assays and establish a medium to high throughput screening platform for drug discovery projects at Janssen Pharmaceutical N.V. Additionally the technology will provide access to the binding kinetics of identified inhibitors, in support of lead optimization.
Technology:
For further informations about FCCS please look at our website:
http://www.intana.de/...
About Intana
Intana Bioscience is a privately?held biotechnology company based in Munich/Martinsried,
Germany. As service provider Intana supports pharmaceutical and biotechnology companies in their drug discovery efforts using Fluorescence Cross Correlation Spectroscopy ? FCCS. The technology can be used to characterize drug target interactions with respect to affinity and kinetic parameters. Measurements can be carried out in cellular lysates, thereby circumventing tedious protein purification and providing physiological conditions for measurements. Customers benefit from short assay development times and precise affinity determination in a physiological environment. Intana receives seed financing by European investors BioM, High?Tech Gründerfonds and Bayern Kapital.
For further inquiries, please contact:
Dr. Frank Becker
Intana Bioscience GmbH
Lochhamer Str. 29a
82152 Planegg
Germany
Phone: +49?(0)89?895572?80
Fax: +49?(0)89?895572?81
info@intana.de
www.intana.de
FCCS is a spectroscopic method to measure the interactions of molecules in solution, based on the sensitive detection of single molecules. The proprietary technology of Intana Bioscience allows FCCS to be performed in cellular lysates, thereby characterizing the interactions between small molecules and their target proteins in approximately physiological conditions.
In the course of this collaboration, Intana will develop assays and establish a medium to high throughput screening platform for drug discovery projects at Janssen Pharmaceutical N.V. Additionally the technology will provide access to the binding kinetics of identified inhibitors, in support of lead optimization.
Technology:
For further informations about FCCS please look at our website:
http://www.intana.de/...
About Intana
Intana Bioscience is a privately?held biotechnology company based in Munich/Martinsried,
Germany. As service provider Intana supports pharmaceutical and biotechnology companies in their drug discovery efforts using Fluorescence Cross Correlation Spectroscopy ? FCCS. The technology can be used to characterize drug target interactions with respect to affinity and kinetic parameters. Measurements can be carried out in cellular lysates, thereby circumventing tedious protein purification and providing physiological conditions for measurements. Customers benefit from short assay development times and precise affinity determination in a physiological environment. Intana receives seed financing by European investors BioM, High?Tech Gründerfonds and Bayern Kapital.
For further inquiries, please contact:
Dr. Frank Becker
Intana Bioscience GmbH
Lochhamer Str. 29a
82152 Planegg
Germany
Phone: +49?(0)89?895572?80
Fax: +49?(0)89?895572?81
info@intana.de
www.intana.de
